Search Site
Home >> Research Area >>Nature Products >> 15,16-Dihydro-15-methoxy-16-oxohardwickiic acid
15,16-Dihydro-15-methoxy-16-oxohardwickiic acid

15,16-Dihydro-15-methoxy-16-oxohardwickiic acid

Catalog No. BCN1612
Size Price Stock
20mg $298 In stock
Related Products

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris

Quality Control of 15,16-Dihydro-15-methoxy-16-oxohardwickiic acid

Chemical structure

15,16-Dihydro-15-methoxy-16-oxohardwickiic acid

15,16-Dihydro-15-methoxy-16-oxohardwickiic acid Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

15,16-Dihydro-15-methoxy-16-oxohardwickiic acid Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties of 15,16-Dihydro-15-methoxy-16-oxohardwickiic acid

Cas No. 115783-35-2 SDF Download SDF
Chemical Name (4aR,5S,6R,8aR)-5-[2-(2-methoxy-5-oxo-2H-furan-4-yl)ethyl]-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalene-1-carboxylic acid
SMILES CC1CCC2(C(C1(C)CCC3=CC(OC3=O)OC)CCC=C2C(=O)O)C
Standard InChIKey LKCDRCCSEGFFNK-CULFUZIZSA-N
Standard InChI InChI=1S/C21H30O5/c1-13-8-10-21(3)15(18(22)23)6-5-7-16(21)20(13,2)11-9-14-12-17(25-4)26-19(14)24/h6,12-13,16-17H,5,7-11H2,1-4H3,(H,22,23)/t13-,16-,17?,20+,21+/m1/s1
Type of Compound Diterpenoids Appearance Powder
Formula C21H30O5 M.Wt 362.5
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other courier with RT , or blue ice upon request.

Preparing Stock Solutions of 15,16-Dihydro-15-methoxy-16-oxohardwickiic acid

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.7586 mL 13.7931 mL 27.5862 mL 55.1724 mL 68.9655 mL
5 mM 0.5517 mL 2.7586 mL 5.5172 mL 11.0345 mL 13.7931 mL
10 mM 0.2759 mL 1.3793 mL 2.7586 mL 5.5172 mL 6.8966 mL
50 mM 0.0552 mL 0.2759 mL 0.5517 mL 1.1034 mL 1.3793 mL
100 mM 0.0276 mL 0.1379 mL 0.2759 mL 0.5517 mL 0.6897 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Preparation of 15,16-Dihydro-15-methoxy-16-oxohardwickiic acid

This product is isolated and purified from the herbs of Callicarpa pedunculata

References on 15,16-Dihydro-15-methoxy-16-oxohardwickiic acid

Azelaic Acid Topical Formulations: Differentiation of 15% Gel and 15% Foam.[Pubmed: 28360967]


In this article, the author reviews topical formulations of azelaic acid used to treat papulopustular rosacea. Emphasis is placed on differences in vehicle technology and potential clinical impact of the possibility for neurosensory cutaneous tolerability reactions.

Synthesis of Apo-13-, and Apo-15-Lycopenoids, Cleavage Products of Lycopene that are Retinoic Acid Antagonists.[Pubmed: 28250025]


Consumption of the tomato carotenoid, lycopene, has been associated with favorable health benefits. Some of lycopenes biological activity may be due to metabolites resulting from cleavage of the lycopene molecule. Because of their structural similarity to the retinoic acid receptor antagonist beta-apo-13-carotenone, the first half putative oxidative cleavage products of the symmetrical lycopene have been synthesized. All transformations proceed in moderate to good yield and some with high stereochemical integrity allowing ready access to these otherwise difficult to obtain terpenoids. In particular, the methods described allow ready access to the trans isomers of citral (geranial) and pseudoionone, important flavor and fragrance compounds that are not readily available isomerically pure and are building blocks for many of the longer apolycopenoids. In addition, all of the apo-11-, apo-13, and apo-15 lycopenals/lycopenones/lycopenoic acids have been prepared. These compounds have been evaluated for their effect on retinoic acid receptor (RAR) induced genes in cultured hepatoma cells and much like beta-apo-13-carotenone, the comparable apo-13-lycopenone, and the apo-15-lycopenoids, behave as RAR antagonists. Furthermore, molecular modelling studies demonstrate that the apo-13-lycopenone efficiently docked into the ligand binding site of RARbeta. Finally, isothermal calorimetry (ITC) studies reveal that apo-13-lycopenone acts as an antagonist of RAR by inhibiting coactivator recruitment to the receptor.

Coenzyme A thioester formation of 11- and 15-oxo-eicosatetraenoic acid.[Pubmed: 28238887]


Release of arachidonic acid (AA) by cytoplasmic phospholipase A2 (cPLA2), followed by metabolism through cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH), results in the formation of the eicosanoids 11-oxo- and 15-oxo-eicosatetraenoic acid (oxo-ETE). Both 11-oxo- and 15-oxo-ETE have been identified in human biospecimens but their function and further metabolism is poorly described. The oxo-ETEs contain an α,β-unsaturated ketone and a free carboxyclic acid, and thus may form Michael adducts with a nucleophile or a thioester with the free thiol of Coenzyme A (CoA). To examine the potential for eicosanoid-CoA formation, which has not previously been a metabolic route examined for this class of lipids, we applied a semi-targeted neutral loss scanning approach following arachidonic acid treatment in cell culture and detected inducible long-chain acyl-CoAs including a predominant AA-CoA peak. Interestingly, a series of AA-inducible acyl-CoAs at lower abundance but higher mass, likely corresponding to eicosanoid metabolites, was detected. Using a targeted LC-MS/MS approach we detected the formation of CoA thioesters of both 11-oxo- and 15-oxo-ETE and monitored the kinetics of their formation. Subsequently, we demonstrated that these acyl-CoA species undergo up to four double bond reductions. We confirmed the generation of 15-oxo-ETE-CoA in human platelets via LC-high resolution MS. Acyl-CoA thioesters of eicosanoids may provide a route to generate reducing equivalents, substrates for fatty acid oxidation, and substrates for acyl-transferases through cPLA2-dependent eicosanoid metabolism outside of the signaling contexts traditionally ascribed to eicosanoid metabolites.

Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.[Pubmed: 28238096]


Increased galectin-3 expression has been currently showed to be associated with poor prognosis in some hematological malignancies, such as acute myeloid leukemia, diffuse large B cell lymphoma. However, little is known about the clinical significance of galectin-3 in patients with acute promyelocytic leukemia (APL). We investigated the concentration of serum galectin-3 and characterized the relationship between galectin-3 and outcome in patients with APL. Higher galectin-3 levels were detected in patients with APL compared with the healthy controls (p < 0.001). Higher galectin-3 levels were closely associated with older ages (p < 0.001), the medical history of psoriasis (p = 0.036), coagulopathy (p = 0.042), and CD34 expression (p = 0.004). Compared with patients with lower galectin-3 levels, those with higher galectin-3 levels had significant shorter overall survival (p = 0.028) and relapse-free survival (p = 0.001). Multivariate analysis showed that serum galectin-3 was an independent unfavorable factor for relapse-free survival in patients with APL treated with all-trans retinoic acid and arsenic trioxide-based frontline therapy. Clinical impact of galectin-3 should be further investigated in patients with APL.

Kewords:

15,16-Dihydro-15-methoxy-16-oxohardwickiic acid ,115783-35-2,Nature Products, supplier, inhibitor,Antagonist,Blocker,Modulator,Agonist, activators, activates, potent, BioCrick

Online Inquiry

Fill out the information below

* Required Fields

CheckCode: